Maria Sandovici
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Sandovici has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth Brouwer
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen , Groningen
5 shared publications - Kornelis S. M. van der Geest
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 shared publications - Peter Heeringa
Department of Pathology and Medical Biology, University Medical Center Groningen, the Netherlands
4 shared publications Elisabeth Brouwer
University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, the Netherlands
3 shared publicationsKornelis S.M. van der Geest
University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, the Netherlands
3 shared publicationsPeter Heeringa
University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 7 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Crosstalk between macrophages and fibroblasts contributes to inflammation and damage in giant cell arteritis
Objectives: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by arterial wall inflammation and remodelling. Macrophages and fibroblasts are abundantly present in arteries affected by GCA, but their crosstalk in GCA pathogenesis is largely unknown. Here we investigated the interaction between macrophages and fibroblasts in GCA-affected arteries and in vitro. Methods: Immunostaining was performed to detect macrophages (CD68, CD206, FRβ), fibroblasts (CD90, CD200), GM-CSF, M-CSF, IL-6, MMP-3 and tenascin-C in GCA-positive temporal arteries (n = 9) and aorta tissues (n = 9). Serum tenascin-C levels were measured by ELISA in GCA patients (n = 36) and healthy controls (n = 46). In vitro, monocytes isolated from peripheral blood mononuclear cells of healthy donors (n = 10) were incubated with GM-CSF or M-CSF for 8 days to induce macrophage differentiation. GM-CSF/M-CSF-macrophage-conditioned medium (MCM) was added to human aortic adventitial fibroblast (HAoAF) cultures for 24 h. mRNA expression of proinflammatory cytokines(IL-6, IL-1β), growth factors (GM-CSF, M-CSF), matrix metalloproteinase (MMP-1, MMP-3), chemokines (CCL2, CX3CL1), extracellular matrix proteins (Col1a1, Col1a2, Col3a1, fibronectin-1, tenascin-C) and phenotypic markers (fibroblast activation protein [FAP], podoplanin [PDPN], α-smooth muscle actin, CD200) in cultured fibroblasts were examined by qPCR. Results: In GCA-affected arteries, pro-inflammatory CD90+IL-6+ fibroblasts, but not pro-resolving CD90+CD200+ fibroblasts, were spatially associated with macrophages. Adventitial CD90+ fibroblasts expressed GM-CSF and/or M-CSF, which linked to macrophage subset distribution. In vitro, both GM-CSF- and, to a lesser extent, M-CSF-derived MCM upregulated mRNA expression of IL-6, GM-CSF, M-CSF, CCL2, PDPN and CD200 in fibroblasts. Upregulation of IL-1β, MMP-3, Col3a1 and tenascin-C and downregulation of FAP in fibroblasts was observed with GM-CSF-derived MCM. Adventitial CD90+ fibroblasts in GCA-affected temporal arteries also expressed MMP-3 and tenascin-C. Serum levels of tenascin-C in patients with treatment-naïve GCA were significantly higher than those in healthy controls, showing a good diagnostic accuracy (area under the curve 0.89). Conclusion: The interaction between fibroblasts and macrophages may contribute to the chronicity and progression of GCA and deserves further investigation. Serum tenascin-C is a candidate biomarker for GCA diagnosis.
- 7 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (3)
Open AccessCrosstalk between macrophages and fibroblasts contributes to inflammation and damage in giant cell arteritis
Objectives: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by arterial wall inflammation and remodelling. Macrophages and fibroblasts are abundantly present in arteries affected by GCA, but their crosstalk in GCA pathogenesis is largely unknown. Here we investigated the interaction between macrophages and fibroblasts in GCA-affected arteries and in vitro. Methods: Immunostaining was performed to detect macrophages (CD68, CD206, FRβ), fibroblasts (CD90, CD200), GM-CSF, M-CSF, IL-6, MMP-3 and tenascin-C in GCA-positive temporal arteries (n = 9) and aorta tissues (n = 9). Serum tenascin-C levels were measured by ELISA in GCA patients (n = 36) and healthy controls (n = 46). In vitro, monocytes isolated from peripheral blood mononuclear cells of healthy donors (n = 10) were incubated with GM-CSF or M-CSF for 8 days to induce macrophage differentiation. GM-CSF/M-CSF-macrophage-conditioned medium (MCM) was added to human aortic adventitial fibroblast (HAoAF) cultures for 24 h. mRNA expression of proinflammatory cytokines(IL-6, IL-1β), growth factors (GM-CSF, M-CSF), matrix metalloproteinase (MMP-1, MMP-3), chemokines (CCL2, CX3CL1), extracellular matrix proteins (Col1a1, Col1a2, Col3a1, fibronectin-1, tenascin-C) and phenotypic markers (fibroblast activation protein [FAP], podoplanin [PDPN], α-smooth muscle actin, CD200) in cultured fibroblasts were examined by qPCR. Results: In GCA-affected arteries, pro-inflammatory CD90+IL-6+ fibroblasts, but not pro-resolving CD90+CD200+ fibroblasts, were spatially associated with macrophages. Adventitial CD90+ fibroblasts expressed GM-CSF and/or M-CSF, which linked to macrophage subset distribution. In vitro, both GM-CSF- and, to a lesser extent, M-CSF-derived MCM upregulated mRNA expression of IL-6, GM-CSF, M-CSF, CCL2, PDPN and CD200 in fibroblasts. Upregulation of IL-1β, MMP-3, Col3a1 and tenascin-C and downregulation of FAP in fibroblasts was observed with GM-CSF-derived MCM. Adventitial CD90+ fibroblasts in GCA-affected temporal arteries also expressed MMP-3 and tenascin-C. Serum levels of tenascin-C in patients with treatment-naïve GCA were significantly higher than those in healthy controls, showing a good diagnostic accuracy (area under the curve 0.89). Conclusion: The interaction between fibroblasts and macrophages may contribute to the chronicity and progression of GCA and deserves further investigation. Serum tenascin-C is a candidate biomarker for GCA diagnosis.
- Open Access
- 21 July 2025
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 11 (1) , 1-12
Towards Therapeutic Targeting of Fibroblasts in Giant Cell Arteritis
Purpose of Review: Giant cell arteritis (GCA) is characterized by chronic vascular inflammation and pathological remodeling. While current therapies primarily rely on broad immunosuppression by glucocorticoids, they fail to halt pathologic remodeling and heal the arteries. Fibroblasts are highly plastic cells that may present the link between chronic inflammation and pathological remodeling. This narrative review aims to give an overview of the possible therapeutic strategies targeting fibroblasts in GCA. Recent Findings: Recent studies have identified and mapped the distribution of various fibroblast subtypes in arteries affected by GCA, highlighting their potential role in both the chronicity of vascular inflammation and pathological remodeling. Advances in molecular tools such as (spatial) transcriptomics and proteomics, along with in vitro models enhance our understanding of the role of fibroblasts in the pathogenesis of GCA and help to identify new fibroblast-related pathways amenable for therapeutic intervention. Summary: Evidence for an effect of pharmacological agents currently used to treat GCA, like glucocorticoids, methotrexate, leflunomide and the interleukin-6 receptor blocker tocilizumab on vascular fibroblasts is limited. New targeted therapies recently approved for GCA, such as the JAK-STAT inhibitor upadacitinib, or other drugs recently or currently being tested in clinical trials offer new opportunities for modulation of vascular fibroblasts in GCA. Depletion of specific pathological fibroblast subtypes or modulation of fibroblast differentiation towards reparative of homeostatic phenotypes, combined with targeted immunosuppression may contribute to vascular healing in GCA.
- 21 July 2025
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 11 (1) , 1-12
Open AccessTowards Therapeutic Targeting of Fibroblasts in Giant Cell Arteritis
Purpose of Review: Giant cell arteritis (GCA) is characterized by chronic vascular inflammation and pathological remodeling. While current therapies primarily rely on broad immunosuppression by glucocorticoids, they fail to halt pathologic remodeling and heal the arteries. Fibroblasts are highly plastic cells that may present the link between chronic inflammation and pathological remodeling. This narrative review aims to give an overview of the possible therapeutic strategies targeting fibroblasts in GCA. Recent Findings: Recent studies have identified and mapped the distribution of various fibroblast subtypes in arteries affected by GCA, highlighting their potential role in both the chronicity of vascular inflammation and pathological remodeling. Advances in molecular tools such as (spatial) transcriptomics and proteomics, along with in vitro models enhance our understanding of the role of fibroblasts in the pathogenesis of GCA and help to identify new fibroblast-related pathways amenable for therapeutic intervention. Summary: Evidence for an effect of pharmacological agents currently used to treat GCA, like glucocorticoids, methotrexate, leflunomide and the interleukin-6 receptor blocker tocilizumab on vascular fibroblasts is limited. New targeted therapies recently approved for GCA, such as the JAK-STAT inhibitor upadacitinib, or other drugs recently or currently being tested in clinical trials offer new opportunities for modulation of vascular fibroblasts in GCA. Depletion of specific pathological fibroblast subtypes or modulation of fibroblast differentiation towards reparative of homeostatic phenotypes, combined with targeted immunosuppression may contribute to vascular healing in GCA.
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4382-4392
Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis
Objective: Giant cell arteritis (GCA) is a systemic vasculitis of large- and medium-sized arteries characterized by granulomatous inflammation and vascular remodelling. Although fibroblasts are the predominant cell type in the adventitia, their role in GCA pathogenesis is largely unknown. This study aimed to investigate the distribution of fibroblast subtypes in relation to vascular remodelling in GCA. Methods: Temporal artery biopsies (TAB) from patients with GCA (n = 9) and controls (n = 15) and aorta tissues from GCA (n = 9)- and atherosclerosis (n = 11)-related aneurysms were examined. Immunohistochemical and immunofluorescence staining for fibroblast subtype markers (CD90, platelet-derived growth factor receptor α [PDGFRA], fibroblast activation protein [FAP], podoplanin [PDPN], CD248, α-smooth muscle actin [α-SMA]), cellular proliferation (Ki67) and remodelling-related growth factors (TGF-β, fibroblast growth factor 21 [FGF21], platelet-derived growth factor B [PDGFB]) were performed to evaluate the distribution of fibroblast subtypes in relation to active remodelling pathways. To evaluate the role of FAP in TGF-β-induced fibroblast proliferation, human aortic adventitial fibroblasts (HAoAF) were stimulated in vitro with TGF-β and transfected with small interfering RNA targeting FAP. Results: In GCA-TAB, CD90+FAP+ activated fibroblasts and CD90+PDPN+ immunofibroblasts were predominantly located in the adventitia. CD90+α-SMA+ myofibroblasts were observed mainly in the intima, and CD90+CD248+ fibroblasts in the adventitia–media border and intima. High FGF21 and PDGFB expression in the intima was associated with intimal hyperplasia in GCA-positive TAB. GCA-affected aortas showed a different landscape of fibroblast subtypes: CD90+FAP+ activated fibroblasts, CD90+PDPN+ immunofibroblasts and CD90+CD248+ fibroblasts accumulated especially in structurally disrupted media. Approximately 80% of proliferative fibroblasts in TAB and aorta were FAP positive. FAP knockdown suppressed TGFβ-induced proliferation of HAoAF in vitro. Conclusion: This study documents a distinct spatial distribution pattern of fibroblast subtypes in GCA-affected arteries. The data suggest different roles for fibroblasts in remodelling of specific arterial vascular beds in GCA.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4382-4392
Open AccessDistinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis
Objective: Giant cell arteritis (GCA) is a systemic vasculitis of large- and medium-sized arteries characterized by granulomatous inflammation and vascular remodelling. Although fibroblasts are the predominant cell type in the adventitia, their role in GCA pathogenesis is largely unknown. This study aimed to investigate the distribution of fibroblast subtypes in relation to vascular remodelling in GCA. Methods: Temporal artery biopsies (TAB) from patients with GCA (n = 9) and controls (n = 15) and aorta tissues from GCA (n = 9)- and atherosclerosis (n = 11)-related aneurysms were examined. Immunohistochemical and immunofluorescence staining for fibroblast subtype markers (CD90, platelet-derived growth factor receptor α [PDGFRA], fibroblast activation protein [FAP], podoplanin [PDPN], CD248, α-smooth muscle actin [α-SMA]), cellular proliferation (Ki67) and remodelling-related growth factors (TGF-β, fibroblast growth factor 21 [FGF21], platelet-derived growth factor B [PDGFB]) were performed to evaluate the distribution of fibroblast subtypes in relation to active remodelling pathways. To evaluate the role of FAP in TGF-β-induced fibroblast proliferation, human aortic adventitial fibroblasts (HAoAF) were stimulated in vitro with TGF-β and transfected with small interfering RNA targeting FAP. Results: In GCA-TAB, CD90+FAP+ activated fibroblasts and CD90+PDPN+ immunofibroblasts were predominantly located in the adventitia. CD90+α-SMA+ myofibroblasts were observed mainly in the intima, and CD90+CD248+ fibroblasts in the adventitia–media border and intima. High FGF21 and PDGFB expression in the intima was associated with intimal hyperplasia in GCA-positive TAB. GCA-affected aortas showed a different landscape of fibroblast subtypes: CD90+FAP+ activated fibroblasts, CD90+PDPN+ immunofibroblasts and CD90+CD248+ fibroblasts accumulated especially in structurally disrupted media. Approximately 80% of proliferative fibroblasts in TAB and aorta were FAP positive. FAP knockdown suppressed TGFβ-induced proliferation of HAoAF in vitro. Conclusion: This study documents a distinct spatial distribution pattern of fibroblast subtypes in GCA-affected arteries. The data suggest different roles for fibroblasts in remodelling of specific arterial vascular beds in GCA.
- Open Access
- 21 May 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (6) , 103574
Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics
- 21 May 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (6) , 103574
Open AccessCurrent evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics
- Open Access
- 11 September 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 140, 103111
Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis
- 11 September 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 140, 103111
Open AccessCytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis
- Open Access
Need and value of targeted immunosuppressive therapy in giant cell arteritis
Despite the heterogeneity of the giant cell arteritis (GCA) at the level of clinical manifestations and the cellular and molecular players involved in its pathogenesis, GCA is still treated with standardised regimens largely based on glucocorticoids (GC). Long-term use of high dosages of GC as required in GCA are associated with many clinically relevant side effects. In the recent years, the interleukin-6 receptor blocker tocilizumab has become available as the only registered targeted immunosuppressive agent in GCA. However, immunological heterogeneity may require different pathways to be targeted in order to achieve a clinical, immunological and vascular remission in GCA. The advances in the targeted blockade of various molecular pathways involved in other inflammatory and autoimmune diseases have catalyzed the research on targeted therapy in GCA. This article gives an overview of the studies with targeted immunosuppressive treatments in GCA, with a focus on their clinical value, including their effects at the level of vascular inflammation.
Open AccessNeed and value of targeted immunosuppressive therapy in giant cell arteritis
Despite the heterogeneity of the giant cell arteritis (GCA) at the level of clinical manifestations and the cellular and molecular players involved in its pathogenesis, GCA is still treated with standardised regimens largely based on glucocorticoids (GC). Long-term use of high dosages of GC as required in GCA are associated with many clinically relevant side effects. In the recent years, the interleukin-6 receptor blocker tocilizumab has become available as the only registered targeted immunosuppressive agent in GCA. However, immunological heterogeneity may require different pathways to be targeted in order to achieve a clinical, immunological and vascular remission in GCA. The advances in the targeted blockade of various molecular pathways involved in other inflammatory and autoimmune diseases have catalyzed the research on targeted therapy in GCA. This article gives an overview of the studies with targeted immunosuppressive treatments in GCA, with a focus on their clinical value, including their effects at the level of vascular inflammation.
- Open Access
- 26 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 4958
Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that affects adults above 50 years of age. In GCA, circulating monocytes are recruited to the inflamed arteries. With cues from the vascular microenvironment, they differentiate into macrophages and play important roles in the pathogenesis of GCA via pro-inflammatory cytokine production and vascular remodeling. However, a deeper understanding of macrophage heterogeneity in GCA pathogenesis is needed to assist the development of novel diagnostic tools and targeted therapies. Here, we review the current knowledge on macrophage heterogeneity and diverse functions of macrophage subsets in the pathogenesis of GCA. We next discuss the possibility to exploit their heterogeneity as a source of novel biomarkers and as targets for nuclear imaging. Finally, we discuss novel macrophage-targeted therapies and future directions for targeting these cells in GCA.
- 26 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 4958
Open AccessFunctionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that affects adults above 50 years of age. In GCA, circulating monocytes are recruited to the inflamed arteries. With cues from the vascular microenvironment, they differentiate into macrophages and play important roles in the pathogenesis of GCA via pro-inflammatory cytokine production and vascular remodeling. However, a deeper understanding of macrophage heterogeneity in GCA pathogenesis is needed to assist the development of novel diagnostic tools and targeted therapies. Here, we review the current knowledge on macrophage heterogeneity and diverse functions of macrophage subsets in the pathogenesis of GCA. We next discuss the possibility to exploit their heterogeneity as a source of novel biomarkers and as targets for nuclear imaging. Finally, we discuss novel macrophage-targeted therapies and future directions for targeting these cells in GCA.
- Open Access
- 1 September 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 123, 102684
Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica
- 1 September 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 123, 102684
Open AccessAssociation of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica
- Open Access
- 1 March 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 135, 111180
The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition
- 1 March 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 135, 111180
Open AccessThe protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition
- Open Access
- 1 August 2020
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 50 (4) , 616-623
Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis
- 1 August 2020
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 50 (4) , 616-623
Open AccessVisual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis